EGFR and non-small cell lung carcinoma: Furthermore, treating EGFR mutant NSCLC cells with a pan‐PI3K inhibitor BKM120 leads to a significant drop of the proliferation ability of PAICS knockdown cells, suggesting the activated PI3K/AKT signaling could compromise the effect of PAICS knockdown.